Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In the years since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began and spread across the globe, lessons have been learned about the challenges and opportunities that a pandemic brings to humankind. Researchers have produced many vaccines at unprecedented speed to protect people, but they have also been cognizant of the challenges presented by a new and unexpected infectious disease. The scope of this review is to examine the path of vaccine discovery so far and identify potential targets. Here, we provide insight into the leading vaccines and their advantages and challenges. We discuss the emerging mutations within the SARS-CoV-2 spike protein and other issues that need to be addressed to overcome coronavirus disease 2019 (COVID-19) completely. Future research is needed to develop a cheap, temperature-stable vaccine providing long-term immunity that protects the upper respiratory tract. (J Allergy Clin Immunol 2022;150:17-21.)

Key words: Approved vaccines, variants of concern, SARS-CoV-2, COVID-19, preclinical vaccines, side effects, vaccine hesitancy, vaccine strategies

The December 2019 emergence of severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) in Wuhan, China, led to a pandemic that continues to be a threat. Coronavirus disease 2019 (COVID-19), associated with the SARS-CoV-2, varies from mild respiratory illness to acute pneumonia and even respiratory failure. SARS-CoV-2 shares more than 70% genetic similarity with SARS coronavirus 1 (SARS-CoV-1), which caused the 2003 outbreak. Although SARS-CoV-1 was more pathogenic, SARS-CoV-2 has a higher reproductive number (R0), indicating a much more efficient spread. Studies have suggested that although both viruses bind to angiotensin-converting enzyme 2 (ACE-2), the structural differences in the surface spike (S) protein of SARS-CoV-2 enable a stronger binding to ACE-2 and greater efficiency at invading host cells. Also, SARS-CoV-2 yields lower neutralizing titers than the SARS-CoV-1 infection. Despite having proof-reading capacity, SARS-CoV-2 can continuously evolve because of its high transmissibility and ability to evade the immune system, giving rise to variants of concern such as the Delta and Omicron strains. Thus, this evolving threat demands that we focus on the challenges facing vaccine research.

The rampant early spread of SARS-CoV-2 made it evident that only an effective vaccine would be able to control the pandemic. The perfect vaccine would be effective after a single inoculation, easy to administer, and stable at a wide range of temperatures, and it would prevent both disease and transmission. Of note, such a vaccine does not currently exist for any infectious disease that we face. The COVID-19 pandemic, however, promoted the rapid development of multiple vaccines against SARS-CoV-2 at an unprecedented speed. The process began in January 2020 and was greatly accelerated by government funding (via Operation Warp Speed [OWS]). The candidates were moved quickly through the preclinical and clinical development pipeline. There are about 183 vaccine candidates, with 148 in clinical development and about 38 approved for use in different countries. In the past, approval of conventional vaccines took about 10 years from the bench to the bedside, whereas the approval of COVID-19 vaccines was achieved in less than 2 years.

Why OWS chose certain vaccine platforms is still open for debate. Initially, the US government took the lead and invested several billion dollars in the development of 3 major vaccine platforms: (1) mRNA vaccines (Moderna and Pfizer), (2) replication-deficient live vectors (Janssen and AstraZeneca), and (3) SARS-CoV-2 S protein–based vaccines (Sanofi-GSK and Novavax). The reasons behind these decisions are not fully transparent and have led to other vaccine approaches being excluded prematurely. For example, the fear of vaccine-associated enhanced respiratory disease, which was observed previously with measles and respiratory syncytial virus inactivated vaccines, may have influenced regulatory bodies to drop certain platforms. Contrary to these concerns, Corbevax, an alum

---

Abbreviations used
- COVID-19: Coronavirus disease 2019
- FCGRT: Fc gamma receptor and transporter
- OWS: Operation Warp Speed
- RBD: Receptor-binding domain
- S: Spike
- SARS: Severe acute respiratory syndrome
- SARS-CoV-1: Severe acute respiratory syndrome coronavirus 1
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

---

From the Department of Microbiology and Immunology, Sidney Kimmel Medical College, and the Jefferson Vaccine Center, Thomas Jefferson University, Philadelphia. This project was financed by a grant from NIH/NIAID 1R21 AI158044-01. Disclosure of potential conflict of interest: M. J. Schnell and D. Kurup are coinventors of the patent application “Coronavirus disease (COVID-19) vaccine.” The remaining author declares that he has no relevant conflicts of interest. Received for publication March 23, 2022; revised May 3, 2022; accepted for publication May 4, 2022. Available online May 23, 2022. Corresponding author: Matthias J. Schnell, PhD, Thomas Jefferson University, Philadelphia, PA 19107. E-mail: Matthias.Schnell@jefferson.edu. The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections 0091-6749/36.00 © 2022 American Academy of Allergy, Asthma & Immunology https://doi.org/10.1016/j.jaci.2022.05.008
The new mRNA technology can cause very unpleasant side effects which, although rarely serious or long-term, have soured a large portion of the population to such vaccines. The mild side effects include pain, redness, or swelling at the site at which the shot was administered and/or tiredness, headache, muscle pain, chills, fever, or nausea throughout the rest of the body; a few rare but severe side effects such as anaphylaxis can also occur.13,14

Notably, there are concerns regarding the long-term immunity provided by these mRNA vaccines, which require a booster after 4 to 6 months.15 It is almost certain that such immunization strategies will fail on account of the low compliance rate observed for influenza vaccination, which requires only yearly boosters.16

In addition to the mRNA and DNA vaccines, viral vector vaccines were also quickly developed during the pandemic. The first widely used viral vector COVID-19 vaccines were based on different replication-deficient adenoviruses (ie, the Johnson & Johnson [Johnson & Johnson/Janssen and Oxford/AstraZeneca vaccines) or replication-competent viruses (eg, the Sputnik-V and CanSino vaccines). Adenoviruses are nonenveloped double-stranded DNA viruses that are most commonly responsible for mild, self-limiting respiratory and ocular infections in humans. Like the mRNA vaccine platform, the adenovirus vaccine platform is relatively new, although the vector has been used for gene therapy. The E1 and/or E3 viral genes enabling replication are deleted and replaced with the transgene of interest to generate a replication-incompetent adenovirus vaccine vector. Adenovirus vectors are relatively safe, as they do not integrate into the host genome (but remain episomal). They are more thermostable than mRNA vaccines, have broad tissue tropism, drive strong expression of the target antigen, and are readily scalable to meet the global demand. The vectors, which are based on the human adenovirus type 26 virus (which is rarely seen in the population) and the chimpanzee adenovirus vector, were used to circumvent the issue of preexisting adenovirus immunity, which affects the immunogenicity of the vaccine.17

Initially, the replication-deficient vectors showed some promise, but the immune responses were not as long-lived as envisioned. For example, waning immune responses were detected as early as 2 months after vaccination with the Johnson & Johnson/Janssen vaccine.2 However, although these vaccines are still used in some countries, they are no longer used in the United States. The widely used Oxford/AstraZeneca vaccine is not recommended in several groups of people on account of very rare but severe side effects (occurring in <1 in 10,000 people). The severe side effects include immune thrombosis associated with adenovirus vaccines, development of menstrual problems in women, capillary leak syndrome, and heart inflammation.15,18

Although these vaccine-associated side effects are unpleasant and occasionally severe, observational cohort studies of patients with COVID-19 after discharge reported symptoms such as fatigue and dyspnea (39%), sleep disturbance (24%), chest pain (12%), and cough (11%) and had a readmission rate of 15% and a mortality rate of 6.7%,19 suggesting that SARS-CoV-2 infections are far more deleterious. The immunity induced by the Oxford/AstraZeneca vaccine against SARS-CoV-2 is also likely limited. The development of attenuated pathogen vaccines based on the measles virus and vesicular stomatitis virus by Merek has been terminated on the basis of disappointing phase 1 immunogenicity results; however, these vaccines are still being pursued by other groups, and the results are pending.20,21

The other COVID-19 vaccines based on recombinant SARS-CoV-2 S proteins are virus-like particles containing all or part of the S protein, subunit protein vaccines, deactivated SARS-CoV-2 viral particles, or novel display platforms such as deactivated rabies virus22,23 (Fig 1, A). Both of the subunit protein vaccines—that from Sanofi-GSK and that from Novavax—faced multiple delays and made it to market only very recently, even though they were generously funded (eg, $1.6 billion for Novavax). Additionally, “deactivated” or “killed” vaccines have a long history of safety and long-term efficacy, which can be lifelong. These platforms have provided some encouraging clinical and/or preliminary results, have minor side effects, and are likely to be more accepted by a larger section of the population because they have been successfully used previously for other vaccines. Whereas the “killed” vaccines provide better temperature stability, their developers still need to provide evidence for (1) manufacturing scalability, (2) long-term stability at 2°C to 8°C, and (3) long-term immunity without requiring regular boosting.

Studies of T-cell responses after natural infection and vaccination suggest that S protein–specific CD4+ and CD8+ T cells are dominant and detected the matrix and nucleoprotein responses to a lesser extent.27 Despite extensive mutations and reduced neutralizing titers to heterologous SARS-CoV-2 strains, the T-cell responses following natural infection or vaccination were cross-reactive to heterologous SARS-CoV-2 strains and retained
FIG 1. A, Different vaccine platforms currently utilized against COVID-19. I, The SARS-CoV-2 trimer is shown in blue in addition to a virus-like particle (VLP) with the trimer anchored within the VLP membrane. II, A lipid-based vehicle containing mRNA encoding the SARS-CoV-2 S protein and a DNA plasmid also encoding the S protein used for vaccination. III, Deactivated SARS-CoV-2 or viral vector–based particles are depicted. An example of the viral vector–based particle is the bullet-shaped viral particle based on the rabies virus; part of the SARS-CoV-2 S1 protein and its native glycoprotein are displayed. IV, Examples of 3 live viral vector vaccines based on adenovirus, measles virus, and vesicular stomatitis virus (left to right). B, Structure of the Omicron S protein with mutations highlighted. The 7T8J structure was used to illustrate mutations in the Delta, Omicron BA.1, and Omicron BA.2 variants. Two monomers are shown as surface topology with the third, highlighting mutations, displayed as a ribbon. S1 domains are displayed as light blue, gray, and green, whereas S2 domains are shown in dark blue, gray, and green. The Delta and Omicron BA.1 variants are compared with one another (top panel), and the Omicron BA.1 and Omicron BA.2 variants are compared with one another (bottom panel). Mutations that are unique (relative to the variant with which it is being compared) to the Delta, Omicron BA.1 and Omicron BA.2 variants, are shown as yellow, red, and blue, respectively (depicted as spheres overlaid on the ribbon). Mutations present in both the Delta and Omicron BA.1 variants are depicted in orange, whereas those common to the Omicron BA.1 and Omicron BA.2 variants are shown in purple. A list of the mutations used in generating this figure can be accessed in Table E2 (available in the Online Repository at www.jacionline.org).
up to 1 year after infection.\textsuperscript{25,26} However, whether this retained T-cell immunity contributes to protection from severe COVID-19 remains to be determined.

An ongoing problem is the potential for emergence of novel SARS-CoV-2 variants that can escape the immune responses induced by the current vaccines or prior infection. Late 2021 saw the emergence of the Omicron variant, which has a great capacity to escape antibody neutralization\textsuperscript{27} because it possesses S protein mutations both within common epitopes on the RBD and significant mutations away from the RBD, which could change the overall behavior of the protein\textsuperscript{28,29} (Fig 1, B). The worldwide spread of the Omicron variant following its emergence and its high potential for breakthrough infections of vaccinated individuals\textsuperscript{30} underscores the ability of SARS-CoV-2 to continue to mutate. It may potentially evade the high levels of population immunity achieved and threaten another such variant that we must be better prepared to control.

The mutations in the Omicron subvariant BA.2 seem to be the most recent set of mutations poised to become the next dominant strain. The subvariant BA.2 has already shown the capacity to reinfect individuals, even those recently infected with Omicron BA.1.\textsuperscript{31} This is likely driven by several new mutations in the antigenic N-terminal domain and RBD,\textsuperscript{32} as demonstrated in Fig 1, B. Breakthrough infections of fully vaccinated individuals have also been documented among those with BA.2 subvariants.\textsuperscript{33,34} Although infections from the BA.1 lineage of Omicron have generally resulted in less severe disease than previous strains, preliminary data from France indicated that individuals with infection traced to the BA.2 lineage of Omicron has resulted in hospitalization at a significantly higher rate (approximately 4 times the rate associated with the BA.1 variant).\textsuperscript{34} Clearly, the continued ability of variants to infect hosts that already possess immunity and recent data indicating a trend toward more severe disease in patients with the BA.2 variant are cause for continued concern. The recent explosion of the BA.2 subvariant BA.2.12.1, growing from 3% to 30% of the sequenced US caseload during April of 2022, underscores the fast-moving nature of this virus’s mutation.\textsuperscript{35}

We know that variants, including those with a high mutation rate that may or may not be controlled by the current vaccines, will continue to emerge. As with many topics related to COVID-19, we can only speculate as to what will happen in the future. The good news is that many of the mutants of SARS-CoV-2 did not spread as much as we anticipated and variants such as Omicron have mostly showed reduced pathogenicity. Of note, it is still unknown whether natural infection induces protective immune responses against proteins other than the S protein that may provide some additional protection. Some results indicate that vaccinating infected people induces better protection than does immunizing subjects twice.\textsuperscript{36,37}

At this point, our opinion is that this new SARS-CoV-2 coronavirus will continue to mutate to a certain extent and will become a seasonal disease like the other 4 human coronaviruses and the seasonal flu. Thus, vaccines will still be needed, and development of a universal SARS-CoV-2 vaccine inducing long-lasting immunity is urgently required to protect vulnerable populations. Additionally, other vaccine platforms, such as live viral vector vaccines, have been developed. Despite these efforts to improve the COVID-19 vaccines, people with deep-rooted antivaccine opinions will continue to oppose vaccination for years to come, which creates other challenges for viral prevention. Lastly, many of the current vaccines provide excellent protection from disease, but none of the commercially available vaccines can prevent the spread of SARS-CoV-2; at best, they reduce the time during which an infected person can transmit the virus to others.\textsuperscript{37,38} The more concerning fact is that immunized people can have an asymptomatic infection and put others—especially the immune suppressed and elderly—at risk.

Consequently, to address the shortcomings of intramuscular vaccination, many researchers are now working toward developing vaccines that target the respiratory mucosa. Recent preclinical assessments of intranasally delivered SARS-CoV-2 S protein–encoding chimpanzee adenoviruses have shown impressive mucosal immunogenicity as well as protection and reduced viral shedding in mice, hamsters, and nonhuman primates. Several studies have demonstrated that intranasal vaccination induces IgG, IgA, B-cell, and T-cell responses that can protect the upper and lower respiratory tract.\textsuperscript{39,40} This may be due to the efficient transport of IgG to the surface of the lung but not the nasal passage owing to the lack of Fc gamma receptor and transporter (FCGRT) in the nasal epithelium. Therefore, vaccination and/or booster via the mucosal membrane, resulting in the induction of IgA, might be the solution, but the longevity of these responses is unknown. Mucosal vaccination has been successfully used with influenza virus but has failed in people with preexisting immunity. Therefore, preexisting immunity might be another concern for viral vectors. Several intranasal vaccines are now being tested in clinical trials.\textsuperscript{41}

The need for additional booster shots has also driven researchers’ efforts to develop a pan-coronavirus vaccine based on the influenza vaccine model, which may mean annual shots. The coronavirus family is a subfamily of orthocoronaviruses, and there are 4 different genera within the subfamily: Alphacoronavirus (which infects all mammals, including humans, causing cold-type symptoms, and most likely has bat origins); Betacoronavirus (Middle East respiratory syndrome, SARS, and SARS-CoV-2); Gammacoronavirus; and Deltacoronavirus (derived from ancestors in pigs and bird species). The genus Betacoronavirus has several sublineages: Embeccovirus (lineage A; some of the common cold viruses), Sarbecovirus (lineage B; SARS and SARS-CoV-2 strains and variations thereof), Merbecovirus (lineage C; Middle East respiratory syndrome), Nobecovirus (lineage D), and a single variety of Hibecovirus (lineage E). Preclinical studies for developing pan-Sarbecovirus vaccines (targeting the RBDs or S protein from different sarbecoviruses) and pan-Betacoronavirus vaccines (targeting undisclosed antigens) are currently under way.\textsuperscript{42}

In summary, many vaccines against COVID-19 are available, but none are perfect. The goal of vaccination is to decrease infections, hospitalizations, and mortality. Thus far, the perfect candidate—a vaccine that is cheap, is temperature stable, and provides long-term immunity (including in the upper respiratory tract)—has yet to be found.

REFERENCES
1. World Health Organization coronavirus. (COVID-19) dashboard. World Health Organization. Available at: https://covid19.who.int/2022. Accessed March 1, 2022.
2. Kurup D, Schnell MJ. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century. Curr Opin Virol 2021;49:52-7.
3. Standl F, Jockel KH, Brune B, Schmidt B, Stang A. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2021;21:e77.
4. Huang Y, Harris BS, Minami SA, Jung S, Shah PS, Nandi S, et al. SARS-CoV-2 spike binding to ACE2 is stronger and longer ranged due to glycan interaction. Biophys J 2022;121:79-90.

5. Chiu WN, Tan CW, Fow R, Kang AEZ, Peng Y, Sivalingam V, et al. Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect 2020;9:1497-505.

6. Awadassied A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 2021;17:8-19.

7. Team VGCVT. World Health Organization. COVID-19 vaccine tracker and landscape. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-vaccine-candidates-2022. Accessed March 9, 2022.

8. Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwitz M, et al. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2021; 39:3053-66.

9. TCs Hospital. Texas Children’s Hospital and Baylor College of Medicine. COVID-19 vaccine technology secures use authorization in India. Available at: https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency 2022. Accessed April 24, 2022.

10. Dolgin E. The tangled history of mRNA vaccines. Nature 2021;597:318-24.

11. Maxmen A. The fight to manufacture COVID vaccines in lower-income countries. Nature 2021;597:455-7.

12. Our World in Data. Coronavirus (COVID-19) vaccinations. Available at: https://ourworldindata.org/covid-vaccinations?country=ETH 2022. Accessed May 3, 2022.

13. Katella K. Yale Medicine. Family Health. Comparing the COVID-19 vaccines: how are they different? March 30. 2022. Available at: https://www.yalemedicine.org/news/covid-19-vaccine-comparison2022. Accessed April 20, 2022.

14. Beauty AL, Peyer ND, Butcher XE, Cocoboba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021;4:e2140364.

15. Tartof SY, Sleazak JM, Fischer H, Hong V, Ackerson BK, Ranaasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 39:1407-16.

16. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML, Treiber K, et al. Barriers of influenza vaccination. J Infect 2022;84:E13-5.

17. Mendonca SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 2021;6:97.

18. Kircheis R. Coagulopathies after vaccination against SARS-CoV-2 may be derived from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-triggered signaling pathways. Int J Mol Sci 2021;22:10791.

19. Chippa V, Aleem A, Anjum F. Post acute coronavirus (COVID-19) syndrome. Treasure Island, FL: StatPearls Publishing; 2022.

20. Vanhoutte F, Liu W, Wiedmann RT, Haspelslagh L, Cao X, Bouindy K, et al. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine 2022;75:103811.

21. Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates; continues development of two investigational therapeutic candidates. https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/2021. Accessed March 14, 2022.

22. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of 3 candidates. NPJ Vaccines 2021;6:28.

23. Kurup D, Malherbe DC, Wirblich C, Lambert R, Ronk AJ, Zabihi Diba L, et al. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog 2021;17:e1009383.

24. Grifoni A, Weiskopf D, Ramrez SJ, Mateus J, Dan JM, Modrbcber CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:1489-1501 e15.

25. Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe 2022.

26. Keeon R, Tincho MB, Ngomt A, Baguma R, Benede N, Suzuki A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 2022;603:488-92.

27. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimyai A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602:657-63.

28. Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 2021;184:2362-71.e9.

29. Laha S, Chakraborty J, Das S, Mannu SK, Biswas S, Chatterjee R. Characterization of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol 2020;85:104445.

30. Domeglo C, Migueires M, Mansuy J-M, Saivin S, Miedouge M, Chapyay-Regaud S, et al. Antibody titres and breakthrough infections with Omicron SARS-CoV-2. J Infect 2022;84:E13-5.

31. Stegger M, Edslove SM, Sieber RN, Cacilia Ingham A, Ng KL, Tang M-HL, et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection 2022 [e-prep ahead of print]. medRxiv https://doi.org/10.1101/2022.02.19.22271112.

32. Yu J, Collier A-RY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med 2022;386:1579-80.

33. Christensena PA, Olsen RN, Long SW, Sheeh T, Davis JI, Ojeda Saavedra M, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas. Am J Pathol 2022;192:64-52.

34. Guettet P, Hong VT, Jimeno MT, Lagier JC, Rossi P, FOURIERN E, et al. The severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December 2021–February 2022 [e-prep ahead of print]. J Med Virol https://doi.org/10.1002/jmv.27760022.

35. US Centers for Disease Control and Prevention. COVID data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#/circuitulatingVariants2022. Accessed April 24, 2022.

36. Brarrondo FJ, Hofmann C, Ali A, Ayoub P, Kohn DB, Yang FO. Previous infection combined with vaccination produces neutralizing antibodies with potency against SARS-CoV-2 Variants. mBio 2021;12:e0265621.

37. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med 2022;386:933-41.

38. Andrews N, Stone J, Kieblock F, Toffa S, Rickard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532-46.

39. Oh Je, Song E, Moriyama M, Wang P, Zhang J, Jiang R, et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal anti- viral IgA. Sci Immunol 2021;6:eabc5129.

40. Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huao TL, et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccines protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med 2021;2:100230.

41. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 2020;183:169-84.e13.

42. Mason T, Israelow B, Suberi A, Zhou L, Reschke M, Pena-Hernandez MA, et al. Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses [e-prep ahead of print]. bioRxiv https://doi.org/10.1101/2021.01.24.477597.

43. National Institutes of Health. Clinical trials. COVID-19 intranasal vaccine. Available at: https://www.clinicaltrials.gov/ct2/results?cond=sars-cov-2&state=&city=&city=

44. Dolgin E. Pan-coronavirus vaccine pipeline takes form. Nat Rev Drug Discov 2022;21:324-6.